2023 Annual Summit on Hematologic Cancers: Incorporation of Novel Therapies in Clinical Practice

Nashville, TN US
September 15, 2023 to September 17, 2023

This CME-accredited activity 2023 Annual Summit on Hematologic Cancers features leading experts in hematologic malignancies who will provide a comprehensive overview of current and emerging strategies for the management of acute myeloid leukemia, acute lymphoblastic leukemia, chronic lymphocytic leukemia, chronic myeloid leukemia, myeloproliferative neoplasms, multiple myeloma, and lymphoma. The goal of this activity is to improve the knowledge and competence of learners to apply practice-changing clinical data and expert recommendations to optimize clinical outcomes for patients with hematologic malignancies. The program features in-depth discussion and analysis of the latest scientific findings and practice-changing advances along with case-based discussion in the field of hematologic malignancies. Expert faculty will aim to place the role of different therapeutic agents in a clinical context and discuss how to utilize these therapeutic options to effectively contribute to patient care.

Target Audience

  • Cancer care professionals
  • Practicing medical oncologists/hematologists
  • Radiation oncologists
  • Pathologists
  • Medical oncology and hematology fellows
  • Oncology nurses
  • Nurse practitioners
  • Physician assistants
  • Pharmacists

 

Learning Objectives

Upon successful completion of this educational activity, participants will be able to:

  • Review strategies for initial therapy and therapies for relapsed disease for patients with various hematologic malignancies
  • Outline efficacy and toxicities of small molecule inhibitors, monoclonal antibodies, antibody drug conjugates, T-cell redirecting bispecific antibodies, and CAR-T for the treatment of patients with hematologic malignancies
  • Apply an individualized treatment plan for patients with ALL, AML, CML, MPN, MM, NHL, HL, based on patient- and disease-related factors 
  • Review evolving role of autologous and allogeneic stem cell transplantation in different hematologic malignancies

You may also be interested in

2023 Summit on Cancer Health Disparities: Reframing and addressing barriers to adoption of precision oncology

This annual oncology conference, 2023 Summit on Cancer Health Disparities: Reframing and addressing barriers to adoption of precision oncology, will feature lectures, panel discussions and debates among leaders across the spectrum of cancer care delivery.
Course summary
Available credit: 
  • 12.50 ABIM MOC II
    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 12.50 Medical Knowledge points in the American Board of Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
  • 12.50 AMA PRA Category 1 Credit™
    The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara Foundation designates this live activity for a maximum of 12.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 12.50 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
  • 12.50 Nursing Contact Hours
    Provider approved by the California Board of Registered Nursing, Provider # CEP17035, for 12.50 Contact Hours.
Course opens: 
01/17/2023
Course expires: 
10/17/2023
Event starts: 
09/15/2023 - 1:30pm PDT
Event ends: 
09/17/2023 - 12:00pm PDT
Cost:
$450.00
Add to calendar: 

Conference chairs: Dr. Nitin Jain, Dr. Navneet Majhail, Dr. Shaji Kumar, & Dr. Sonali Smith

September 15, 2023

 

1:30 pm – 3:00 pm: Session 1: ALL

Chairs: Dr. Lori Muffly

1:30 pm - 1:45 pm: How do I incorporate CAR T in my clinical practice?

1:45 pm - 2:00 pm: Anything new in T-ALL therapy?

2:00 pm - 2:20 pm: Case #1

2:20 pm - 2:40 pm: Case #2

2:40 pm - 3:00 pm: Case #3

3:00 pm – 3:30 pm: Break

3:30 pm – 5:00 pm: Session 2: Aggressive Lymphomas

Chairs: Dr. Nirav Shah

3:30 pm - 3:45 pm: Sequencing of CAR-T

3:45 pm - 4:00 pm: Focus on elderly patients and CAR-T

4:00 pm - 4:20 pm: Case #1

4:20 pm - 4:40 pm: Case #2

4:40 pm - 5:00 pm: Case #3

5:00 pm - 6:00 pm: Abstract Session

September 16

 

7:30 am – 8:15 am: Industry sponsored symposium

8:30 am – 10:00 am: Session 3: Multiple myeloma – Newly Dx

Chairs: Dr. Muzaffar H. Qazilbash & Dr. Noopur Raje

8:30 am - 8:45 am: Triplets or quadruplets – what is the right approach for newly diagnosed MM? - Dr. Noopur Raje

8:45 am - 9:00 am: Transplant for MM – does it still have a role? - Dr. Muzaffar H. Qazilbash

9:00 am - 9:15 am: Maintenance approaches for MM – one drug or two? - Dr. Shaji Kumar

9:15 am - 9:35 am: Case #1

9:40 am - 10:00 am: Case #2

10:00 am – 10:30 am: Break

10:30 am – 12:00 pm: Session 4: AML/MDS

Chairs: Dr. Uma Borate

10:30 am - 10:45 am: Frontline Therapy of AML in 2023 - Dr. Tapan Kadia

10:45 am - 11:00 am: Updates in treatment of MDS - Dr. Hetty Carraway

11:00 am - 11:20 am: Case #1

11:20 am - 11:40 am: Case #2

11:40 am - 12:00 pm: Case #3

12:00 pm – 12:45 pm: Lunch/Industry sponsored symposium 

1:00 pm - 1:30 pm (Keynote) Treatment of Hodgkin lymphoma in 2023 - Dr. Ranjana H. Advani

1:30 pm – 3:00 pm: Session 5: CLL

Chairs: Dr. Nitin Jain  

1:30 pm - 1:45 pm: BTK or BCL2i or Both for Frontline CLL 

1:45 pm - 2:00 pm: Pirtobrutinib, CAR T and others. How to incorporate in practice?

2:00 pm - 2:20 pm: Case #1

2:20 pm - 2:40 pm: Case #2

2:40 pm - 3:00 pm: Case #3

3:00 pm – 3:30 pm: Break

3:30 pm – 5:00 pm: Session 6: Low-grade Lymphomas

Chairs: TBD

3:30 pm - 3:45 pm: Are bispecifics really going to have a role in indolent lymphomas?

3:45 pm - 4:00 pm: Sequencing of treatments in 2L+ settings

4:00 pm - 4:20 pm: Case #1

4:20 pm - 4:40 pm: Case #2

4:40 pm - 5:00 pm: Case #3

September 17

 

7:30 am – 8:15 am: Industry sponsored symposium

8:30 am – 10:00 am: Session 7: CML/MPN

Chairs: Dr. Gabriela Hobbs and Dr. Naveen Pemmaraju

8:30 am - 8:45 am: Incorporating novel JAKi and other therapies in MF management 

8:45 am - 9:00 am: Unanswered questions in CML in 2023

9:00 am - 9:20 am: Case #1

9:20 am - 9:40 am: Case #2

9:40 am - 10:00 am: Case #3

10:00 am – 10:30 am: Break

10:30 am – 12:00 pm: Session 8: Multiple myeloma – R/R

Chairs: Dr. Shaji Kumar

10:30 am - 10:45 am: Management of early relapses in myeloma-choosing the right combination - Dr. Natalie Callander

10:45 am - 11:00 am: Integrating immunotherapies into treatment of relapsed MM – CART, ADC and bispecifics

11:00 am - 11:15 am: Non-immune approaches for advanced myeloma - Dr. Ajay Nooka

11:15 am - 11:35 am: Case #1

11:40 am - 12:00 Pm: Case #2

Gaylord Opryland Resort & Convention Center
2800 Opryland Dr
Nashville, TN 37214
United States

IDENTIFICATION AND MITIGATION OF POTENTIAL CONFLICT OF INTEREST:

All conflict of interest has been identified and mitigated for individuals in control of contents.

PLANNING COMMITTEE DISCLOSURE STATEMENT:

None of the members of the planning committee, nor any member of their immediate families, have a relevant financial interest in or affiliation with any commercial supporter of this educational activity and/or with the manufacturer(s) of commercial products and/or providers of any commercial services discussed in this educational activity.

 

Course Director(s)

Shaji Kumar, MD

has a financial relationship (Professional Services) with Consulting/Advisory Board participation: (with no personal payments) Abbvie, Amgen, BMS, Janssen,  Roche-Genentech, Takeda, Astra-Zeneca, Bluebird Bio, Epizyme, Secure Biotherapeutics and (with personal payment) Oncopeptides, Beigene, Antengene ;.
has a financial relationship (Grant Or Contract) with Research funding for clinical trials to the institution: Abbvie, Amgen, BMS, Carsgen,  Janssen,  ,  Astra-Zeneca, Novartis, Roche-Genentech,  Takeda, Tenebio, Molecular Templates;.
Moderator(s)

Gabriela Hobbs, MD

has a financial relationship (Financial Support) with Novartis;.
has a financial relationship (Financial Support) with Cogent;.
has a financial relationship (Financial Support) with Abbvie;.
has a financial relationship (Financial Support) with Pharmaxis;.
has a financial relationship (Financial Support) with BMS;.
has a financial relationship (Financial Support) with Incyte;.
has a financial relationship (Financial Support) with Pfizer;.
has a financial relationship (Financial Support) with Morphosys;.
Speaker(s)

Ranjana Advani, Professor of Medicine at Stanford University

has a financial relationship (Other) with Epizyme;.
has a financial relationship (Financial Support) with Regeneron;.
has a financial relationship (Financial Support) with Merck;.
has a financial relationship (Financial Support) with Gilead;.
has a financial relationship (Other) with Genentech/Roche;.
has a financial relationship (Financial Support) with Conjupro;.
has a financial relationship (Financial Support) with Cyteir;.
has a financial relationship (Other) with Bristol Myers Squibb/Celgene;.
has a financial relationship (Other) with BeiGene;.
has a financial relationship (Financial Support) with Daiichi;.
has a financial relationship (Other) with Incyte;.
has a financial relationship (Other) with ADCT;.
has a financial relationship (Financial Support) with Seattle Genetics;.
has a financial relationship (Other) with Daiichi;.

Natalie Callander

has no relevant financial relationships to disclose at this time.

Available Credit

  • 12.50 ABIM MOC II
    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 12.50 Medical Knowledge points in the American Board of Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
  • 12.50 AMA PRA Category 1 Credit™
    The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara Foundation designates this live activity for a maximum of 12.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 12.50 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
  • 12.50 Nursing Contact Hours
    Provider approved by the California Board of Registered Nursing, Provider # CEP17035, for 12.50 Contact Hours.

If you are interested in exhibiting at this meeting, please visit our exhibit page here - https://education.binayfoundation.org/exhibit-information

 

Price

Cost:
$450.00
Please login or register to take this course.

NOTICE TO HCPS EMPLOYED BY THE INDUSTRY:

If you are employed by industry, including pharmaceuticals and biotech companies, you must pay the INDUSTRY REGISTRATION FEE to participate in any meeting organized by the Binaytara Foundation. If you misrepresented yourself as a healthcare provider not employed by the industry and failed to pay the Industry registration fee, the following fees apply:

  • If your company has purchased a display table at the event, you will be billed the full INDUSTRY REGISTRATION FEE plus a fine equivalent to the full industry registration fee for that event = 2 X the industry registration fee.
  • If your company has NOT purchased a display table at the event AND you attended the meeting without paying a full industry registration fee, you will be billed a full GENERAL DISPLAY FEE for that event. 

Any outstanding display fee, registration fee, and fines must be paid before the industry employee or the company will be able to attend/display at our conferences again.

CANCELLATION POLICY

You may cancel your enrollment at any time. Cancellation fees apply as below:

  • 50% of the paid registration fee will be refunded if registration is cancelled six weeks before the conference.
  • No refunds will be issued if registration is cancelled after that date.  

No credits will be offered if you do not complete all required steps of this activity which include registration, participation in the live activity, and completion of pre & post tests as well as course evaluations.